Suppr超能文献

在中空纤维感染模型中,万古霉素与阿米卡星联合使用对浮游菌与生物膜生长菌的差异活性

Differential Activity of the Combination of Vancomycin and Amikacin on Planktonic vs. Biofilm-Growing Bacteria in a Hollow Fiber Infection Model.

作者信息

Broussou Diane C, Lacroix Marlène Z, Toutain Pierre-Louis, Woehrlé Frédérique, El Garch Farid, Bousquet-Melou Alain, Ferran Aude A

机构信息

INTHERES, INRA, ENVT, Université de Toulouse, Toulouse, France.

Vétoquinol, Global Drug Development, Lure, France.

出版信息

Front Microbiol. 2018 Mar 27;9:572. doi: 10.3389/fmicb.2018.00572. eCollection 2018.

Abstract

Combining currently available antibiotics to optimize their use is a promising strategy to reduce treatment failures against biofilm-associated infections. Nevertheless, most assays of such combinations have been performed on planktonic bacteria exposed to constant concentrations of antibiotics over only 24 h and the synergistic effects obtained under these conditions do not necessarily predict the behavior of chronic clinical infections associated with biofilms. To improve the predictivity of combination assays for bacterial biofilms, we first adapted a previously described Hollow-fiber (HF) infection model by allowing a biofilm to form before drug exposure. We then mimicked different concentration profiles of amikacin and vancomycin, similar to the free plasma concentration profiles that would be observed in patients treated daily over 5 days. We assessed the ability of the two drugs, alone or in combination, to reduce planktonic and biofilm-embedded bacterial populations, and to prevent the selection of resistance within these populations. Although neither amikacin nor vancomycin exhibited any bactericidal activity on in monotherapy, the combination had a synergistic effect and significantly reduced the planktonic bacterial population by -3.0 to -6.0 log CFU/mL. In parallel, no obvious advantage of the combination, as compared to amikacin alone, was demonstrated on biofilm-embedded bacteria for which the addition of vancomycin to amikacin only conferred a further maximum reduction of 0.3 log CFU/mL. No resistance to vancomycin was ever found whereas a few bacteria less-susceptible to amikacin were systematically detected before treatment. These resistant bacteria, which were rapidly amplified by exposure to amikacin alone, could be maintained at a low level in the biofilm population and even suppressed in the planktonic population by adding vancomycin. In conclusion, by adapting the HF model, we were able to demonstrate the different bactericidal activities of the vancomycin and amikacin combination on planktonic and biofilm-embedded bacterial populations, suggesting that, for biofilm-associated infections, the efficacy of this combination would not be much greater than with amikacin monotherapy. However, adding vancomycin could reduce possible resistance to amikacin and provide a relevant strategy to prevent the selection of antibiotic-resistant bacteria during treatments.

摘要

联合使用目前可用的抗生素以优化其使用,是减少针对生物膜相关感染治疗失败的一种有前景的策略。然而,大多数此类联合用药的试验是在仅暴露于恒定浓度抗生素24小时的浮游细菌上进行的,在这些条件下获得的协同效应不一定能预测与生物膜相关的慢性临床感染的情况。为了提高针对细菌生物膜联合用药试验的预测性,我们首先对先前描述的中空纤维(HF)感染模型进行了改进,使生物膜在药物暴露前形成。然后我们模拟了阿米卡星和万古霉素的不同浓度曲线,类似于在接受为期5天每日治疗的患者中观察到的游离血浆浓度曲线。我们评估了这两种药物单独或联合使用时,减少浮游细菌和生物膜内细菌数量以及防止这些群体中耐药性产生的能力。虽然阿米卡星和万古霉素单药治疗时均未表现出任何杀菌活性,但联合用药具有协同效应,可使浮游细菌数量显著减少3.0至6.0 log CFU/mL。同时,与单独使用阿米卡星相比,联合用药在生物膜内细菌方面未显示出明显优势,在阿米卡星中添加万古霉素仅使生物膜内细菌数量最多进一步减少0.3 log CFU/mL。从未发现对万古霉素耐药的情况,而在治疗前系统性地检测到了一些对阿米卡星敏感性较低的细菌。这些耐药细菌通过单独暴露于阿米卡星会迅速扩增,通过添加万古霉素可使其在生物膜群体中维持在低水平,甚至在浮游群体中被抑制。总之,通过改进HF模型,我们能够证明万古霉素和阿米卡星联合用药对浮游细菌和生物膜内细菌群体具有不同的杀菌活性,这表明对于生物膜相关感染,这种联合用药的疗效不会比阿米卡星单药治疗有太大提高。然而,添加万古霉素可以降低对阿米卡星可能产生的耐药性,并为在治疗期间防止抗生素耐药细菌的产生提供一种相关策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01d5/5880918/1b0c09f3d04a/fmicb-09-00572-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验